Shattuck Labs Q1 FY26 net loss widens to $14.8 million; R&D expenses rise to $10.9 million

Shattuck Labs, Inc.

Shattuck Labs, Inc.

STTK

0.00
  • Shattuck Labs posted a net loss of USD 14.8 million, or USD 0.13 per share, for first-quarter 2026, versus a net loss of USD 13.7 million, or USD 0.27 per share, a year earlier.
  • R&D expense rose to USD 10.9 million from USD 9.9 million, while G&A expense edged up to USD 4.6 million from USD 4.5 million.
  • Cash and cash equivalents and short-term investments climbed to USD 90.4 million as of March 31, 2026, from USD 60.9 million a year earlier.
  • Enrollment finished in Phase 1 trial of SL-325, with a full dataset expected in second-quarter 2026; Phase 2 trial in Crohn’s disease is slated to start in third-quarter 2026, subject to positive Phase 1 data and regulatory alignment.
  • Management said trial readout will include safety and tolerability, pharmacokinetics, receptor occupancy and duration, pharmacodynamics, and immunogenicity; cash runway is expected to fund operations into 2029 assuming full exercise of outstanding common stock warrants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070615PRIMZONEFULLFEED9714980) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.